CompoAtlas

MINERVA RESEARCH LABS - GOLD COLLAGEN FORTE

Food supplement declared in France, declaration No 2024-6-659

MINERVA RESEARCH LABS - GOLD COLLAGEN FORTE, from MINERVA RESEARCH LABS LIMITED, is a food supplement declared in France. Status: withdrawal from the market announced for 10 July 2028. Main ingredients: Euterpe oleracea 30 mg per day, Punica granatum 20 mg per day, Borago officinalis 12.5 mg per day, Oenothera biennis 12.5 mg per day, Piper nigrum 1.5 mg per day. 1 point in its composition requires a check (prohibited substance, dose or novel food). 1 rule of use applies to its ingredients (limits and warnings).

Brand
not provided
Food business operator placing the product on the market
MINERVA RESEARCH LABS LIMITED
Status
Withdrawal from the market announced for 10 July 2028
Form
Bottle
Daily dose
50 ml (1 bouteille) par jour
Intended populations
Men, Women
Not recommended (according to the manufacturer)
Adolescents (under 18), Taking medication
Objectives stated by the manufacturer (these are not authorised claims)
Antioxidant, Hair and nails, Skin

Declaration 228965, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Euterpe oleracea Mart.FruitPression à froid30 mg
Punica granatum L.FruitPression à froid20 mg
Borago officinalis L.Graine (huile)Pression à froid12.5 mg
Oenothera biennis L.Graine (huile)Pression à froid12.5 mg
Piper nigrum L.FruitPoudre (de plantes séchées ou broyées)1.5 mg

Other active ingredients

NamePer day
Collagène hydrolysénot declared
Carnosinenot declared
Resvératrolnot declared
Acide hyaluroniquenot declared
N-acétylglucosaminenot declared
Ubiquinonenot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
D-biotinBiotin (vitamin B8)no limit (insufficient data)dose annulled by the French Council of State in 2011
beta-caroteneβ-Caroteneno limit (insufficient data)no fixed dose
cupric gluconateCopper5,000 µg2,000 µg
pyridoxine hydrochlorideVitamin B612 mg2 mg
L-ascorbic acidVitamin Cno limit (insufficient data)180 mg
cholecalciferolVitamin D100 µg (4,000 IU)5 µg (200 IU)
D-alpha-tocopherolVitamin E300 mg30 mg
zinc gluconateZinc25 mg15 mg

Additives

E330, E322, E296, E960, E160d

Other ingredients

eau, polysaccharose

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Label warnings

Ne pas dépasser la dose journalière recommandée. Les compléments alimentaires ne doivent pas se substituer à une alimentation variée et équilibrée et à un mode de vie sain. Ne pas laisser à la portée des jeunes enfant. Réservé à l'adulte. Pendant la grossesse, l'allaitement consultez votre médecin avant de prendre GOLD COLLAGEN® FORTE. Les personnes prenant des médicaments ne devraient consommer le produit que sous contrôle médical. Déconseillé aux fumeurs. Conserver dans un endroit frais et sec, à l'abri de la lumière. Consommer en moins de 24 h après ouverture d'une bouteille.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Euterpe oleracea Mart.
    Read the warning, when it applies and the studies cited

    ACAI – EUTERPE OLERACEA

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (derMarderosian and Beutler 2008).

    Sources cited by Health Canada (1)
    • derMarderosian A, Beutler JA, editors. The Review of Natural Products. [Acai: Date of issue January 2008]. St Louis (MO): Facts and Comparisons, Wolters Kluwer Health; Printed in 2008 and Updated to April 2012.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (derMarderosian and Beutler 2008).

    Sources cited by Health Canada (1)
    • derMarderosian A, Beutler JA, editors. The Review of Natural Products. [Acai: Date of issue January 2008]. St Louis (MO): Facts and Comparisons, Wolters Kluwer Health; Printed in 2008 and Updated to April 2012.

    Health Canada monograph dated 24 April 2026

  • Punica granatum L.
    Read the warning, when it applies and the studies cited
  • Borago officinalis L.
    Read the warning, when it applies and the studies cited
  • Oenothera biennis L.
    Read the warning, when it applies and the studies cited
  • Collagène hydrolysé
    Read the warning, when it applies and the studies cited

    Hydrolyzed Collagen

    Route of administration: Oral

    Cautions and warnings

    Condition of application: Joint pain.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

    Applies to products providing more than 2.8 g hydrolyzed collagen, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Shils et al. 2006; Goldman and Ausiello 2004).

    Sources cited by Health Canada (2)
    • Goldman L, Ausiello D, editors. Cecil Textbook of Medicine, Volume 1, 22nd edition. Philadelphia (PA): Saunders; 2004.
    • Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ, editors. Modern Nutrition in Health and Disease, 10th edition. Philadelphia (PA): Lippincott Williams and Wilkins, 2006.

    Known adverse reactions

    When using this product you may experience gastrointestinal discomfort/disturbances (Moskowitz 2000).

    Sources cited by Health Canada (1)
    • Moskowitz RW. Role of collagen hydrolysate in bone and joint disease. Seminars in Arthritis and Rheumatism 2000;30(2):87-99. PubMed Randomised trial

    Health Canada monograph dated 28 March 2024

  • Ubiquinone
    Read the warning, when it applies and the studies cited

    Coenzyme Q10 (UBIQUINONE-10)

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).

    Sources cited by Health Canada (2)
    • Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
    • Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial

    Applies to products providing more than 100 mg of Coenzyme Q10 per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).

    Sources cited by Health Canada (3)
    • Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
    • Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
    • Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report

    Condition of application: Migraine prophylaxis/prevention.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.

    Health Canada monograph dated 31 January 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “MINERVA RESEARCH LABS - GOLD COLLAGEN FORTE: composition and regulation”, https://compoatlas.com/en/supplements/products/228965-minerva-research-labs-gold-collagen-forte, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line